Evidence map›Paper›PMID 42652903›Full record

ArticleLife (Basel, Switzerland)2026

LDN-27219 Modulates High-Glucose-Induced Endothelial Bioenergetic Remodeling and MitoSOX Red Fluorescence.

Augusta Volkevičiūtė, Deimantė Puzinovė, Zbigniev Balion, Nikolas Žumbakis, Patricija Lapinskaitė, Agilė Tunaitytė, Olena Kutakh, Edgaras Stankevičius, Estéfano Pinilla, Ulf Simonsen

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Augusta VolkevičiūtėPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.
Deimantė PuzinovėPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.
Zbigniev BalionPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.
Nikolas ŽumbakisPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.
Patricija LapinskaitėPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.
Agilė TunaitytėPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.
Olena KutakhPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.
Edgaras StankevičiusPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.ORCID 0000-0003-2210-708X
Estéfano PinillaDepartment of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, DK-8000 Aarhus, Denmark.ORCID 0000-0002-7852-992X
Ulf SimonsenPreclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, LT-50162 Kaunas, Lithuania.ORCID 0000-0002-2169-7666

Funding

Research Council of Lithuania "The Role of Endothelial Transglutaminase-2 Signaling in Development of Neurovascular Dysfunction" (S-MIP-23-94).
6 · The paper itself

Abstract

backgroundEndothelial dysfunction is a key feature of diabetic vascular disease and is associated with high-glucose-induced changes in endothelial energy metabolism and redox balance. Transglutaminase-2 has been implicated in vascular stress responses, but its contribution to endothelial adaptation to high glucose remains incompletely defined.

methodsEA.hy926 endothelial cells were cultured under normoglycaemic (NG) or high-glucose conditions and treated with LDN-27219 at 20 µg/mL (48.9 µM). Cellular reducing capacity, total protein content, mitochondrial respiration, MitoSOX Red fluorescence, and selected cytokine and adhesion-marker secretion were assessed.

resultsHigh glucose shifted cells toward a more glycolytic basal phenotype, increased MitoSOX Red fluorescence, and reduced glycolytic stress responsiveness compared with NG conditions. LDN-27219 had limited effects under NG conditions but, under high-glucose conditions, reduced basal respiration, maximal respiration, ATP-linked oxygen consumption, and spare respiratory capacity, while partially restoring stressed extracellular acidification. LDN-27219 also reduced high-glucose-induced MitoSOX Red fluorescence, although this cannot be interpreted as definitive evidence of reduced mitochondrial superoxide production because mitochondrial membrane potential was not measured. No statistically significant changes were detected in the selected inflammatory or adhesion markers.

conclusionsLDN-27219 modifies endothelial bioenergetic and oxidant-associated fluorescence responses under high-glucose conditions.

Indexed as

cellular reducing capacitydiabetic vascular dysfunctionendothelial bioenergeticsendothelial cellsextracellular acidification ratehigh glucoseLDN-27219mitochondrial respirationMitoSOX Red fluorescencetransglutaminase-2

Identifiers

PMID42652903
PMCPMC13514542

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.